A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma

ClinicalTrials.gov ID: NCT05757102

Public ClinicalTrials.gov record NCT05757102. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 16, 2026, 8:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, 24-week, Randomized, Double-blind, Parallel-group Bayesian Dynamic Borrowing Study Comparing the Efficacy, Safety, Tolerability and Pharmacokinetics of FF/UMEC/VI With FF/VI in 12-17-year-old Participants With Inadequately Controlled Asthma on Stable Maintenance Therapy With ICS/LABA

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The primary purpose of this study is to evaluate the effects of Fluticasone Furoate (FF)/ Umeclidinium (UMEC)/ Vilanterol (VI) on lung function compared with FF/VI after 24 weeks of treatment.

Study identification

NCT ID: NCT05757102
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 3
Lead sponsor: GlaxoSmithKline; Industry
Enrollment: 138 participants

Conditions and interventions

Conditions

Asthma

Interventions

FF/UMEC/VI Drug
ELLIPTA Device
FF/VI Drug

Drug · Device

Eligibility (public fields only)

Age range: 12 Years to 17 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 24, 2023 (Actual)
Primary completion: Jan 26, 2027 (Estimated)
Completion: Jan 28, 2027 (Estimated)
Last update posted: Sep 30, 2026

2023 – 2027

United States locations

U.S. sites: 28
U.S. states: 16
U.S. cities: 26

Facility	City	State	ZIP	Site status
GSK Investigational Site	Birmingham	Alabama	35244	Recruiting
GSK Investigational Site	Mobile	Alabama	36608	Recruiting
GSK Investigational Site	Paradise Valley	Arizona	85253	Recruiting
GSK Investigational Site	Bakersfield	California	93301-4205	Recruiting
GSK Investigational Site	Huntington Beach	California	92647	Recruiting
GSK Investigational Site	Mission Viejo	California	92691	Recruiting
GSK Investigational Site	Rolling Hills Estates	California	90274	Completed
GSK Investigational Site	Colorado Springs	Colorado	80909	Recruiting
GSK Investigational Site	Aventura	Florida	33180	Completed
GSK Investigational Site	Miami	Florida	33165	Recruiting
GSK Investigational Site	Miami	Florida	33173	Completed
GSK Investigational Site	Miami	Florida	33174	Recruiting
GSK Investigational Site	Savannah	Georgia	31406	Completed
GSK Investigational Site	Normal	Illinois	61761	Recruiting
GSK Investigational Site	Owensboro	Kentucky	42301	Recruiting
GSK Investigational Site	Columbia	Missouri	65203	Completed
GSK Investigational Site	Missoula	Montana	59808	Recruiting
GSK Investigational Site	The Bronx	New York	10461-1119	Recruiting
GSK Investigational Site	Cincinnati	Ohio	45229	Recruiting
GSK Investigational Site	Cleveland	Ohio	44106	Recruiting
GSK Investigational Site	Dayton	Ohio	45404	Completed
GSK Investigational Site	Oklahoma City	Oklahoma	73120-9350	Recruiting
GSK Investigational Site	Charleston	South Carolina	29420	Recruiting
GSK Investigational Site	Dallas	Texas	75225-6301	Recruiting
GSK Investigational Site	Kerrville	Texas	78028	Recruiting
GSK Investigational Site	Plano	Texas	75034	Completed
GSK Investigational Site	Waco	Texas	76712	Completed
GSK Investigational Site	Milwaukee	Wisconsin	53226	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 39 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05757102, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 30, 2026 · Synced Oct 16, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT05757102 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →